{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:11:44Z","timestamp":1791223904037,"version":"4.1.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,2,16]],"date-time":"2016-02-16T00:00:00Z","timestamp":1455580800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s40273-015-0348-x","type":"journal-article","created":{"date-parts":[[2016,2,16]],"date-time":"2016-02-16T10:45:51Z","timestamp":1455619551000},"page":"363-391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France"],"prefix":"10.1007","volume":"34","author":[{"given":"Sylvain","family":"Druais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Doutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Cognet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Godet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Lan\u00e7on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Samalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Guillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,16]]},"reference":[{"key":"348_CR1","unstructured":"World Health Organisation (WHO). Schizophrenia: Fact sheet N\u00b0397 [database on the Internet] 2014 [cited 04\/11\/2014]. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs397\/en\/ ."},{"key":"348_CR2","unstructured":"World Health Organization (WHO). Schizophrenia and public health. 1996."},{"key":"348_CR3","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). Commission de la Transparence\u2014Avis du 1er f\u00e9vrier 2012 : XEPLION. 2012."},{"key":"348_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/epirev\/mxn011","volume":"30","author":"WW Eaton","year":"2008","unstructured":"Eaton WW, Martins SS, Nestadt G, et al. The burden of mental disorders. Epidemiol Rev. 2008;30:1\u201314.","journal-title":"Epidemiol Rev."},{"key":"348_CR5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","volume":"30","author":"J McGrath","year":"2008","unstructured":"McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67\u201376.","journal-title":"Epidemiol Rev."},{"issue":"1","key":"348_CR6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/1471-244X-12-193","volume":"12","author":"P Switaj","year":"2012","unstructured":"Switaj P, Anczewska M, Chrostek A, et al. Disability and schizophrenia: a systematic review of experienced psychosocial difficulties. BMC Psychiatry. 2012;12(1):193.","journal-title":"BMC Psychiatry."},{"key":"348_CR7","unstructured":"Direction G\u00e9n\u00e9rale de la Sant\u00e9, INSERM. Rapport du GTNDO: Analyse des connaissances disponibles sur des probl\u00e8mes de sant\u00e9 s\u00e9lectionn\u00e9s, leurs d\u00e9terminants, et les strat\u00e9gies de sant\u00e9 publique\u2014D\u00e9finition d\u2019objectifs. 2003."},{"key":"348_CR8","unstructured":"World Health Organization (WHO). The global burden of disease: 2004 update. 2008."},{"key":"348_CR9","unstructured":"Minist\u00e8re du Travail de l\u2019Emploi et de la Sant\u00e9. Plan psychiatrique et sant\u00e9 mentale 2011\u20132015. 2012."},{"issue":"Suppl 1","key":"348_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.2005.01202.x","volume":"12","author":"P Andlin-Sobocki","year":"2005","unstructured":"Andlin-Sobocki P, Jonsson B, Wittchen HU, et al. Cost of disorders of the brain in Europe. Eur J Neurol. 2005;12(Suppl 1):1\u201327.","journal-title":"Eur J Neurol."},{"key":"348_CR11","unstructured":"Llorca PM. https:\/\/www.orpha.net\/data\/patho\/FR\/fr-schizo.pdf . Encyclop\u00e9nie Orphanet. 2004."},{"key":"348_CR12","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). Guide ALD 23 \u00abSchizophr\u00e9nies\u00bb. 2007."},{"key":"348_CR13","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). Commission de la Transparence\u2014Avis du 23 septembre 2009: ZYPADHERA. 2009."},{"key":"348_CR14","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). Commission de la Transparence\u2014Avis du 5 mai 2010: RISPERDALCONSTA L.P. 2010."},{"key":"348_CR15","unstructured":"The Court of Auditors. L\u2019organisation des soins psychiatriques: les effets du plan \u201cpsychiatrie et sant\u00e9 mentale\u201d. 2011."},{"issue":"9657","key":"348_CR16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31\u201341.","journal-title":"Lancet."},{"issue":"7","key":"348_CR17","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7326\/0003-4819-157-7-201210020-00525","volume":"157","author":"L Hartling","year":"2012","unstructured":"Hartling L, Abou-Setta AM, Dursun S, et al. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med. 2012;157(7):498\u2013511.","journal-title":"Ann Intern Med."},{"issue":"1","key":"348_CR18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2011.143","volume":"18","author":"T Kishimoto","year":"2013","unstructured":"Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013;18(1):53\u201366.","journal-title":"Mol Psychiatry."},{"key":"348_CR19","doi-asserted-by":"crossref","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). Commission de la Transparence\u2014Avis du 30 novembre 2011. 2011.","DOI":"10.1016\/S1261-694X(11)70231-0"},{"key":"348_CR20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/1471-244X-13-340","volume":"13","author":"PM Llorca","year":"2013","unstructured":"Llorca PM, Abbar M, Courtet P, et al. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:340.","journal-title":"BMC Psychiatry."},{"key":"348_CR21","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1192\/bjp.195.52.s63","volume":"52","author":"JM Kane","year":"2009","unstructured":"Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009;52:S63\u20137.","journal-title":"Br J Psychiatry Suppl."},{"key":"348_CR22","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1192\/bjp.195.52.s20","volume":"52","author":"PM Haddad","year":"2009","unstructured":"Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry Suppl. 2009;52:S20\u20138.","journal-title":"Br J Psychiatry Suppl."},{"issue":"7","key":"348_CR23","first-page":"A549","volume":"16","author":"JJY Lee","year":"2013","unstructured":"Lee JJY, Gauthier A, Curtis S, Musingarimi P, Price M. Cost Effectiveness of Paliperidone Palmitate in National Health Service (NHS) Wales: a cost utility analysis based on the National Institute for Health and Care Excellence (NICE) Core Model for the Management of Schizophrenia. Value Health. 2013;16(7):A549.","journal-title":"Value Health."},{"issue":"7\u20138","key":"348_CR24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3917\/jgem.097.0421","volume":"27","author":"S Raymond","year":"2009","unstructured":"Raymond S, Martin M, Netillard C, et al. Schizophr\u00e9nie : \u00e9valuation du co\u00fbt de la prise en charge. Journal d\u2019Economie M\u00e9dicale. 2009;27(7\u20138):421\u201333.","journal-title":"Journal d\u2019Economie M\u00e9dicale."},{"issue":"2","key":"348_CR25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0013-7006(05)82390-5","volume":"31","author":"PM Llorca","year":"2005","unstructured":"Llorca PM, Miadi-Fargier H, Lancon C, et al. Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation. Encephale. 2005;31(2):235\u201346.","journal-title":"Encephale."},{"issue":"2\u20133","key":"348_CR26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.schres.2011.10.022","volume":"134","author":"L Grimaldi-Bensouda","year":"2012","unstructured":"Grimaldi-Bensouda L, Rouillon F, Astruc B, et al. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res. 2012;134(2\u20133):187\u201394.","journal-title":"Schizophr Res."},{"key":"348_CR27","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). A methodological guide\u2014choices in methods for economic evaluation. 2012."},{"issue":"5","key":"348_CR28","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3111\/13696998.2012.681531","volume":"15","author":"A Mehnert","year":"2012","unstructured":"Mehnert A, Nicholl D, Pudas H, et al. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. J Med Econ. 2012;15(5):844\u201361.","journal-title":"J Med Econ."},{"issue":"5","key":"348_CR29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40258-013-0050-0","volume":"11","author":"J Zeidler","year":"2013","unstructured":"Zeidler J, Mahlich J, Greiner W, et al. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany. Appl Health Econ Health Policy. 2013;11(5):509\u201321.","journal-title":"Appl Health Econ Health Policy."},{"issue":"Suppl 4","key":"348_CR30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0013-7006(13)70121-0","volume":"39","author":"L Samalin","year":"2013","unstructured":"Samalin L, Abbar M, Courtet P, et al. French Society for Biological Psychiatry and Neuropsychopharmacology task force: formal consensus for the prescription of depot antipsychotics. Encephale. 2013;39(Suppl 4):189\u2013203.","journal-title":"Encephale."},{"key":"348_CR31","unstructured":"RISPERDALCONSTA: summary of product characteristics [database on the Internet] 2014 [cited 07\/11\/2014]. Available from: http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/frames.php?specid=68901873&typedoc=R&ref=R0241528.htm ."},{"key":"348_CR32","unstructured":"XEPLION: summary of product characteristics. [database on the Internet] 2014 [cited 07\/11\/2014]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002105\/WC500103317.pdf ."},{"key":"348_CR33","unstructured":"ZYPADHERA: summary of product characteristics. [database on the Internet]2014 [cited 07\/11\/2014]. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000890\/human_med_001188.jsp&mid=WC0b01ac058001d124 ."},{"key":"348_CR34","unstructured":"ABILIFY MAINTENA: summary of product characteristics. [database on the Internet] 2014 [cited 07\/11\/2014]. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002755\/human_med_001711.jsp&mid=WC0b01ac058001d124 ."},{"key":"348_CR35","unstructured":"HALDOL DECANOAS: summary of product characteristics [database on the Internet] 2014 [cited 07\/11\/2014]. Available from: http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/frames.php?specid=61505095&typedoc=R&ref=R0223383.htm ."},{"key":"348_CR36","unstructured":"ZYPREXA: summary of product characteristics. [database on the Internet] 2014 [cited 07\/11\/2014]. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000115\/human_med_001189.jsp&mid=WC0b01ac058001d124 ."},{"issue":"3","key":"348_CR37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1017\/S109285291300014X","volume":"18","author":"SM Stahl","year":"2013","unstructured":"Stahl SM, Morrissette DA, Citrome L, et al. \u201cMeta-guidelines\u201d for the management of patients with schizophrenia. CNS Spectr. 2013;18(3):150\u201362.","journal-title":"CNS Spectr."},{"issue":"2\u20133","key":"348_CR38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","volume":"116","author":"D Hough","year":"2010","unstructured":"Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2\u20133):107\u201317.","journal-title":"Schizophr Res."},{"issue":"1","key":"348_CR39","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","volume":"35","author":"G Pandina","year":"2011","unstructured":"Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):218\u201326.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"9896","key":"348_CR40","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362.","journal-title":"Lancet."},{"key":"348_CR41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1477-7525-6-105","volume":"6","author":"A Briggs","year":"2008","unstructured":"Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes. 2008;6:105.","journal-title":"Health Qual Life Outcomes."},{"issue":"1","key":"348_CR42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euroneuro.2004.07.003","volume":"15","author":"P Chue","year":"2005","unstructured":"Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2005;15(1):111\u20137.","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol."},{"issue":"2","key":"348_CR43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/YIC.0b013e32835b091f","volume":"28","author":"P Fusar-Poli","year":"2013","unstructured":"Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol. 2013;28(2):57\u201366.","journal-title":"Int Clin Psychopharmacol."},{"key":"348_CR44","doi-asserted-by":"crossref","first-page":"407171","DOI":"10.1155\/2012\/407171","volume":"2012","author":"S Zhornitsky","year":"2012","unstructured":"Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr Res Treatment. 2012;2012:407171.","journal-title":"Schizophr Res Treatment."},{"issue":"1","key":"348_CR45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1744-859X-12-32","volume":"12","author":"JM Olivares","year":"2013","unstructured":"Olivares JM, Sermon J, Hemels M, et al. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry. 2013;12(1):32.","journal-title":"Ann Gen Psychiatry."},{"key":"348_CR46","unstructured":"CHU Clermont-Ferrand. CHU Request for hospitalisation duration: patients hospitalis\u00e9s en 2012 et 2013 en Psychiatrie B, avec code diagnostique F200 \u00e0 209 ou F220 \u00e0 F229. 2014."},{"issue":"4","key":"348_CR47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00004850-200107000-00001","volume":"16","author":"S Kasper","year":"2001","unstructured":"Kasper S, Rosillon D, Duchesne I, et al. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol. 2001;16(4):179\u201387.","journal-title":"Int Clin Psychopharmacol."},{"issue":"10","key":"348_CR48","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","volume":"64","author":"S Saha","year":"2007","unstructured":"Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123\u201331.","journal-title":"Arch Gen Psychiatry."},{"issue":"6","key":"348_CR49","first-page":"32","volume":"26","author":"MC Bralet","year":"2000","unstructured":"Bralet MC, Yon V, Loas G, et al. Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients. Encephale. 2000;26(6):32\u201341.","journal-title":"Encephale."},{"issue":"4","key":"348_CR50","first-page":"329","volume":"25","author":"F Casadebaig","year":"1999","unstructured":"Casadebaig F, Philippe A. Mortality in schizophrenic patients. 3\u00a0years follow-up of a cohort. Encephale. 1999;25(4):329\u201337.","journal-title":"Encephale."},{"key":"348_CR51","doi-asserted-by":"crossref","first-page":"d5422","DOI":"10.1136\/bmj.d5422","volume":"343","author":"U Hoang","year":"2011","unstructured":"Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999\u20132006. BMJ. 2011;343:d5422.","journal-title":"BMJ."},{"key":"348_CR52","unstructured":"Indice \u00e0 la consommation depuis 2000. [database on the Internet] 2015 [cited 29\/01\/2015]."},{"key":"348_CR53","unstructured":"French Health Insurance (Assurance Maladie). AMELIE\u2014Bases des M\u00e9dicaments et Informations Tarifaires. 2015. 02\/01\/2015."},{"key":"348_CR54","unstructured":"Clozapine: summary of product characteristics [database on the Internet] 2014 [cited 07\/11\/2014]. Available from: http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/frames.php?specid=64814983&typedoc=R&ref=R0213721.htm ."},{"key":"348_CR55","unstructured":"French Health Insurance (Assurance Maladie). AMELIE - Tarifs conventionnels des m\u00e9decins sp\u00e9cialiste [database on the Internet]. 2015. Available from: http:\/\/www.ameli.fr\/professionnels-de-sante\/medecins\/votre-convention\/tarifs\/index.php ."},{"key":"348_CR56","unstructured":"Costs of ALD in 2009. [database on the Internet] 2014. Available from: http:\/\/www.ameli.fr\/l-assurance-maladie\/statistiques-et-publications\/donnees-statistiques\/affection-de-longue-duree-ald\/cout\/cout-des-ald-en-2009.php ."},{"key":"348_CR57","unstructured":"Court of Auditores (Cour des comptes). L\u2019organisation des soins psychiatriques : les effets du plan \u201cpsychiatrie et sant\u00e9 mentale\u201d [2005\u20132010]. 2011; Available from: http:\/\/www.sante.gouv.fr\/IMG\/pdf\/L_organisation_des_soins_psychiatriques_les_effets_du_plan_Psychiatrie_et_sante_mentale_2005-2010.pdf ."},{"key":"348_CR58","unstructured":"Tarifs. [database on the Internet] 2014 [cited 13\/11\/2014]. Available from: http:\/\/www.ameli.fr\/professionnels-de-sante\/medecins\/votre-convention\/tarifs\/index.php ."},{"key":"348_CR59","doi-asserted-by":"crossref","unstructured":"Ricci P, Chantry M, Detournay B, et al. Reimbursed health expenditure of people treated for diabetes: 2001 and 2007 Entred studies. Pratiques et Organisation des Soins. 2010;41(1). http:\/\/fulltext.bdsp.ehesp.fr\/Cnamts\/POS\/2010\/1\/1.pdf .","DOI":"10.3917\/pos.411.0001"},{"issue":"8","key":"348_CR60","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hec.635","volume":"10","author":"E Fenwick","year":"2001","unstructured":"Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779\u201387.","journal-title":"Health Econ."},{"key":"348_CR61","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). Valeurs de r\u00e9f\u00e9rences pour l\u2019\u00e9valuation \u00e9conomique en sant\u00e9. Revue de la litt\u00e9rature. 2014."},{"issue":"1","key":"348_CR62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11314070-000000000-00000","volume":"28","author":"E Deconinck","year":"2010","unstructured":"Deconinck E, Miadi-Fargier H, Pen CL, et al. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation. Pharmacoeconomics. 2010;28(1):35\u201346.","journal-title":"Pharmacoeconomics."},{"issue":"9","key":"348_CR63","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3111\/13696998.2013.823869","volume":"16","author":"TR Einarson","year":"2013","unstructured":"Einarson TR, Pudas H, Zilbershtein R, et al. Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland. J Med Econ. 2013;16(9):1096\u2013105.","journal-title":"J Med Econ."},{"issue":"7","key":"348_CR64","doi-asserted-by":"crossref","first-page":"A459","DOI":"10.1016\/j.jval.2014.08.1266","volume":"17","author":"M Kolek","year":"2014","unstructured":"Kolek M, Duba J, Vesela S, et al. Cost-utility analysis of long-acting paliperidone in comparison with oral risperidone, oral paliperidone and long long-acting risperidone in the maintenance treatment of schizophrenia in the Czech Republic. Value in Health. 2014;17(7):A459.","journal-title":"Value in Health"},{"issue":"8","key":"348_CR65","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3111\/13696998.2014.917089","volume":"17","author":"L Citrome","year":"2014","unstructured":"Citrome L, Kamat SA, Sapin C, et al. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. J Med Econ. 2014;17(8):567\u201376.","journal-title":"J Med Econ."},{"issue":"5","key":"348_CR66","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.eurpsy.2008.12.002","volume":"24","author":"JM Olivares","year":"2009","unstructured":"Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 2009;24(5):287\u201396.","journal-title":"Eur Psychiatry."},{"issue":"3","key":"348_CR67","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4088\/JCP.v67n0317","volume":"67","author":"H Ascher-Svanum","year":"2006","unstructured":"Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453\u201360.","journal-title":"J Clin Psychiatry."},{"issue":"2","key":"348_CR68","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1176\/appi.ajp.2009.07081221","volume":"167","author":"JM Kane","year":"2010","unstructured":"Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167(2):181\u20139.","journal-title":"Am J Psychiatry."},{"issue":"2","key":"348_CR69","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40258-013-0016-2","volume":"11","author":"E Achilla","year":"2013","unstructured":"Achilla E, McCrone P. The cost effectiveness of long-acting\/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy. 2013;11(2):95\u2013106.","journal-title":"Appl Health Econ Health Policy."},{"issue":"12","key":"348_CR70","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1177\/070674370605101207","volume":"51","author":"P Huguelet","year":"2006","unstructured":"Huguelet P, Khan AN, Morand-Collomb S, et al. Prevalence and characteristics of neuroleptic association in a patient cohort with psychotic disorders. Can J Psychiatry. 2006;51(12):774\u201382.","journal-title":"Can J Psychiatry."},{"key":"348_CR71","unstructured":"Abilify Maintena (aripiprazole)\u2014Authorisation details [database on the Internet] 2014 [cited 19\/11\/2014]. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002755\/human_med_001711.jsp&mid=WC0b01ac058001d124 ."},{"issue":"4","key":"348_CR72","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.euroneuro.2006.09.005","volume":"17","author":"JM Haro","year":"2007","unstructured":"Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007;17(4):235\u201344.","journal-title":"Eur Neuropsychopharmacol."},{"key":"348_CR73","unstructured":"Clinical study report synopsis [database on the Internet] 2014 [cited 10\/11\/2014]. Available from: https:\/\/clinicaltrials.gov\/ct2\/bye\/uQoPWw4lZXc6edhHld-gWQ7xUXU3lB1ymB7gmXNgZdD9jdiudh9k6GgzwU6eBc8uB1glT490dhzzdUV9VLPD1WeKDzqcR48ayUgWi7PxQ7V9gCBWyN6edhHuB7Lzs8gDR4tWRC5O1WgC8pxE6hB\/SVD3FioH5TD3Z6p3WQh8J676NQ7gkB-5JdcBJwhGvQ13zwNz5dcxzno3kdhLeihGW6D3edp3WQh8JwoyziNHuihzZdp3Z6p3S67gLwUyzdNgznh9NnoPl6D3FT7LEih9mwS3Z6p3FBckeTN9EQoyzdNzk ."},{"key":"348_CR74","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2147\/NDT.S5463","volume":"6","author":"R Lorenzo Di","year":"2010","unstructured":"Di Lorenzo R, Brogli A. Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiatr Dis Treat. 2010;6:573\u201381.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"6","key":"348_CR75","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1192\/bjp.bp.107.037184","volume":"192","author":"M Smith","year":"2008","unstructured":"Smith M, Hopkins D, Peveler RC, et al. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192(6):406\u201311.","journal-title":"Br J Psychiatry."},{"key":"348_CR76","unstructured":"French Health Insurance (Assurance Maladie). AMELIE - Base des m\u00e9dicaments et informations tarifaires\u2014PLAI 150\u00a0mg [database on the Internet] [cited 02\/01\/2015]. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/\/fiche\/index_fic_medisoc.php?p_code_cip=3400941766930&p_site= ."},{"key":"348_CR77","unstructured":"French Health Insurance (Assurance Maladie). AMELIE\u2014Base des m\u00e9dicaments et informations tarifaires - PLAI 100\u00a0mg [database on the Internet] [cited 02\/01\/2015]. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/\/fiche\/index_fic_medisoc.php?p_code_cip=3400941766879&p_site= ."},{"key":"348_CR78","unstructured":"French Health Insurance (Assurance Maladie). AMELIE\u2014Base des m\u00e9dicaments et informations tarifaires - PLAI 75\u00a0mg [database on the Internet] [cited 02\/01\/2015]. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/\/fiche\/index_fic_medisoc.php?p_code_cip=3400941766701&p_site= ."},{"key":"348_CR79","unstructured":"French Health Insurance (Assurance Maladie). AMELIE\u2014Base des m\u00e9dicaments et informations tarifaires\u2014RLAI 37.5\u00a0mg\/2\u00a0ml [database on the Internet] [cited 02\/01\/2015]. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/\/fiche\/index_fic_medisoc.php?p_code_cip=3400936249363&p_site= ."},{"key":"348_CR80","unstructured":"French Health Insurance (Assurance Maladie). AMELIE\u2014Base des m\u00e9dicaments et informations tarifaires - Risperidone oral 4\u00a0mg [database on the Internet] [cited 02\/01\/2015]. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/\/fiche\/index_fic_medisoc.php?p_code_cip=3400938178883&p_site= ."},{"key":"348_CR81","unstructured":"French Health Insurance (Assurance Maladie). AMELIE\u2014Base des m\u00e9dicaments et informations tarifaires\u2014ALAI 400\u00a0mg [database on the Internet] [cited 02\/01\/2015]. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm\/\/fiche\/index_fic_sp_cip.php?p_code_cip=3400927721908&p_menu=FICHE&p_site= ."},{"key":"348_CR82","unstructured":"French Health Insurance (Assurance Maladie). AMELIE\u2014Base des m\u00e9dicaments et informations tarifaires\u2014Aripripazole oral 15\u00a0mg [database on the Internet] [cited 02\/01\/2015]. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/\/fiche\/index_fic_medisoc.php?p_code_cip=3400936407862&p_site=AMELI ."},{"key":"348_CR83","unstructured":"French Health Insurance (Assurance Maladie). AMELIE\u2014Base des m\u00e9dicaments et informations tarifaires\u2014OO 10\u00a0mg [database on the Internet] [cited 02\/01\/2015]. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/\/fiche\/index_fic_medisoc.php?p_code_cip=3400939371962&p_site= ."},{"key":"348_CR84","unstructured":"French Health Insurance (Assurance Maladie). AMELIE\u2014Base des m\u00e9dicaments et informations tarifaires\u2014HLAI 5\u00a0ml\/inj. [database on the Internet] [cited 02\/01\/2015]. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/\/fiche\/index_fic_medisoc.php?p_code_cip=3400932635108&p_site= ."},{"key":"348_CR85","unstructured":"French Health Insurance (Assurance Maladie). AMELIE\u2014Base des m\u00e9dicaments et informations tarifaires\u2014Clozapine 100\u00a0mg [database on the Internet]. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/\/fiche\/index_fic_medisoc.php?p_code_cip=3400935704719&p_site= ."},{"key":"348_CR86","unstructured":"PARKINANE LP 5\u00a0mg: summary of product characteristics [database on the Internet] 2011 [cited 19\/11\/2014]. Available from: http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/frames.php?specid=66238671&typedoc=R&ref=R0189092.htm ."},{"key":"348_CR87","unstructured":"LEPTICUR 10\u00a0mg: summary of product characteristics [database on the Internet] 2014 [cited 19\/11\/2014]. Available from: http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/frames.php?specid=66631817&typedoc=R&ref=R0144737.htm ."},{"key":"348_CR88","unstructured":"AKINETON L.P. 4\u00a0mg: summary of product characteristics [database on the Internet] 2006 [cited 19\/11\/2014]. Available from: http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/frames.php?specid=66782153&typedoc=R&ref=R0131797.htm ."},{"key":"348_CR89","unstructured":"Druet C RC, Romon I, Assogba F, Bourdel-Marchasson I, et al. Echantillon national t\u00e9moin repr\u00e9sentatif des personnes diab\u00e9tiques, Entred 2007\u20132010. Institut de veille sanitaire. 2012:8. http:\/\/www.invs.sante.fr\/Publications-et-outils\/Guides\/Echantillon-national-temoin-representatif-des-personnes-diabetiques-Entred-2007-2010"},{"key":"348_CR90","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). Recommandation de bonnes pratiques\u2014Surpoids et ob\u00e9sit\u00e9 de l\u2019adulte: prise en charge m\u00e9dicale de premier recours. 2011."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0348-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-015-0348-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0348-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T17:00:25Z","timestamp":1567616425000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-015-0348-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,16]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["348"],"URL":"https:\/\/doi.org\/10.1007\/s40273-015-0348-x","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,16]]}}}